Sandoz CEO Richard Saynor will present the company's strategy to seize what he calls an unprecedented "golden decade" opportunity during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Speaking at the conference, Saynor will highlight Sandoz's unique position as the only pure-play biosimilar and generic company and its readiness to capture a significant share of a market opportunity exceeding $600 billion as reference medicines lose exclusivity over the next ten years.
The company has delivered consistently on commitments since becoming a standalone entity in 2023, establishing what Saynor describes as a "unique leading position" in the affordable medicines market. This market accounts for 80% of medicines used globally at just 30% of total cost, giving Sandoz substantial impact on healthcare accessibility. The presentation slides detailing this strategy will be available after Richard Saynor's presentation at https://www.sandoz.com/investors/events-presentations.
In its first two years as an independent company, Sandoz achieved several strategic milestones that position it for scale and impact. The company broke ground on a major new sterile biosimilars production center in Brnik, Slovenia, part of a multi-site project representing over $1.1 billion in total investment to expand its European biosimilar hub. Sandoz also completed the acquisition of Just-Evotec Biologics' site and capabilities in Toulouse, France, and launched six biosimilars in 2025 alone, including three in the fourth quarter.
Three pillars now define Sandoz's global leadership: global scale with 1,300 products supplied to over 100 countries, unique positioning as the only pure-play biosimilar and generic company with reliable execution, and a respected leadership team backed by more than 20,000 employees worldwide. The company maintains a robust manufacturing and supply network that supports this scale.
Financially, Sandoz has demonstrated strong momentum with 2024 sales reaching $10 billion, driven by double-digit growth in biosimilars. The company maintains an attractive balance sheet to support investment plans and holds the number one position in the European market, which serves as its home base and global leadership cornerstone. Sandoz forecasts mid-single digit annual sales growth through 2028 at constant exchange rates, with core EBITDA margin expansion projected to reach 24% to 26% by 2028.
The company's strategy focuses on growing its core generics business while pursuing a focused loss of exclusivity coverage approach centered on oral solids and injectables. With approximately 1,300 products marketed worldwide and a pipeline exceeding 400 assets, Sandoz targets nearly two-thirds of the $340 billion generic opportunity. The company also maintains a longer-term focus on the emerging GLP-1 market. In biosimilars, Sandoz continues building on its pioneer status with a portfolio of 13 molecules in nearly 100 countries and a rapidly-growing pipeline targeting approximately 60% of the $322 billion biosimilar opportunity.
A significant challenge in the biosimilar market is what Sandoz calls the "biosimilar void" - more than 50 biologics facing loss of exclusivity in the next seven years currently have no biosimilar planned due to high clinical development costs. The company has led industry efforts to streamline biosimilar development through regulatory changes that could substantially decrease both cost and time to market without compromising quality, safety, or efficacy. These efforts could help fill the void and increase patient access to affordable biologic medicines.
Saynor concludes that Sandoz is "poised to seize the unprecedented market opportunity over the next decade" and will lead efforts to make the coming ten years the "golden decade" of affordable healthcare. The company's progress can be followed through its investor relations materials available at https://www.sandoz.com/investors.
